. . . "After 24 hours, 84% of a 30 mg dose of cevimeline was excreted in urine."@en . . . "5 ± 1 hours"@en . "For the treatment of symptoms of dry mouth in patients with Sjögren's Syndrome."@en . . . . . "approved"@en . . . . . . . . . "107233-08-9"@en . . . . "Cevimelina"@en . . . . . . . . . "Cevimeline is a parasympathomimetic and muscarinic agonist, with particular effect on M3 receptors. It is indicated by the Food and Drug Administration for the treatment of dry mouth associated with Sj\u00F6gren's syndrome. [Wikipedia]"@en . . "* 6 L/kg"@en . "Humans and other mammals"@en . . "Cevimelinum"@en . "Muscarinic agonists such as cevimeline bind and activate the muscarinic M1 and M3 receptors. The M1 receptors are common in secretory glands (exocrine glands such as salivary and sweat glands), and their activation results in an increase in secretion from the secretory glands. The M3 receptors are found on smooth muscles and in many glands which help to stimulate secretion in salivary glands, and their activation generally results in smooth muscle contraction and increased glandular secretions. Therefore, as saliva excretion is increased, the symptoms of dry mouth are relieved."@en . . "Rapidly absorbed with peak concentration after 1.5 to 2 hours"@en . . . "Cevimeline"@en . "2-Methyspiro(1,3-oxathiolane-5,3)quinuclidine"@en . . "< 20%"@en . . . . . . . . . " "@en . . "Sni 2011"@en . . . . . .